Company intelligence / Profile preview
ProQR Therapeutics
Leiden, Netherlandsproqr.com ↗
- Ownership
- Public · PRQR
- Employees
- ~166
- Development stage
- Preclinical
01
Overview
ProQR is advancing its Axiomer ADAR-mediated RNA editing platform and pipeline, with up to four clinical data readouts anticipated in 2025 and 2026, including topline data for their NTCP program. Their lead program AX-0810 targeting NTCP for Cholestatic diseases is on track for CTA filing in Q2 2025 with first clinical data anticipated in Q4 2025[4].
- Therapeutic areas
- GastroenterologyCardiovascularNeurologyRare Diseases
- Modalities
- RNA therapeuticsRNA editing oligonucleotides
- Industry
- Biotech
02
Drug pipeline
28 assets27 more assets in the full pipeline.
03
Partnerships
Eli Lilly and CompanyRett Syndrome Research Trust
04
Financials
- Market cap
- $187.7M
- Total revenue
- $17.1M
- Enterprise value
- $71.6M
Beyond the preview
Go deeper on ProQR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProQR Therapeutics.